Suppr超能文献

选择性雌激素受体调节剂(SERM)拉索昔芬对雌性大鼠的生殖毒性评估。

Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats.

作者信息

Terry K K, Cappon G D, Hurtt M E, Tassinari M S, Gupta U

机构信息

Pfizer Global Research and Development, Groton, Connecticut 06340, USA.

出版信息

Birth Defects Res B Dev Reprod Toxicol. 2004 Jun;71(3):150-60. doi: 10.1002/bdrb.20009.

Abstract

BACKGROUND

Lasofoxifene is a nonsteroidal selective estrogen receptor modulator (SERM). With high affinity to the alpha and beta human estrogen receptors and greater potency than other SERMs, lasofoxifene is potentially a superior treatment for postmenopausal osteoporosis. In light of the known effects of estrogen-modulating compounds on female reproductive indices, two studies were conducted to evaluate the effects of lasofoxifene on female rat cyclicity, reproduction, and parturition.

METHODS

One study evaluated effects of lasofoxifene on estrous cyclicity, and the second study assessed effects on implantation and parturition. In the cyclicity study, lasofoxifene was administered to female rats at doses of 0.1, 0.3, and 1.0 mg/kg/day for 14 consecutive days. After treatment, there was a 3-week reversibility phase followed by a mating phase. In the implantation study, lasofoxifene was administered to pregnant female rats at doses of 0.01, 0.03, and 0.1 mg/kg/day for 7 consecutive days (gestation day [GD] 0-6). Some animals were euthanized on GD 21, and the remainder of the group was allowed to deliver the F1 generation. Several developmental indices were evaluated in the F1 pups through post-natal day (PND) 21.

RESULTS

In the cyclicity study, all lasofoxifene-treated females were anestrous by Study Day 7 (1.0 mg/kg) or 9 (0.3 and 0.1 mg/kg). The reversibility phase resulted in restoration of normal estrous cycles by the end of 1 (0.1 mg/kg) or 2 weeks (0.3 and 1.0 mg/kg). During the mating phase, no adverse effects occurred in pregnancy success or reproductive parameters. In the implantation study, all doses of lasofoxifene increased pre- and post-implantation losses, increased gestation length, and reduced litter size. None of the developmental parameters measured on the F1 generation was adversely affected.

CONCLUSION

Lasofoxifene reversibly altered the estrous cycle and inhibited implantation, consistent with what would be expected from a member of the SERM class.

摘要

背景

拉索昔芬是一种非甾体类选择性雌激素受体调节剂(SERM)。拉索昔芬对人雌激素α和β受体具有高亲和力,且比其他SERM效力更强,它可能是绝经后骨质疏松症的一种更优治疗药物。鉴于雌激素调节化合物对雌性生殖指标的已知影响,开展了两项研究以评估拉索昔芬对雌性大鼠月经周期、生殖和分娩的影响。

方法

一项研究评估拉索昔芬对发情周期的影响,另一项研究评估其对着床和分娩的影响。在周期研究中,以0.1、0.3和1.0mg/kg/天的剂量连续14天给雌性大鼠施用拉索昔芬。治疗后,有一个为期3周的可逆期,随后是交配期。在着床研究中,以0.01、0.03和0.1mg/kg/天的剂量连续7天(妊娠第0至6天)给妊娠雌性大鼠施用拉索昔芬。一些动物在妊娠第21天安乐死,该组其余动物则让其分娩F1代。在出生后第21天之前对F1幼崽的几个发育指标进行了评估。

结果

在周期研究中,到研究第7天(1.0mg/kg)或第9天(0.3和0.1mg/kg)时,所有接受拉索昔芬治疗的雌性大鼠均处于静止发情期。可逆期结束时,0.1mg/kg组在1周内、0.3和1.0mg/kg组在2周内恢复了正常发情周期。在交配期,妊娠成功率或生殖参数未出现不良反应。在着床研究中,所有剂量的拉索昔芬均增加了着床前和着床后的损失,延长了妊娠期,并减少了窝仔数。F1代所测的发育参数均未受到不利影响。

结论

拉索昔芬可逆地改变发情周期并抑制着床,这与SERM类药物的预期作用一致。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验